21st Century Cures: BIO Comments on FDA Draft Guidance Qualification Process for Drug Development Tools
Re: Docket No. FDA–2020-D-0529: FDA Draft Guidance, Qualification Process for Drug Development Tools
February 14, 2020
Dear Sir/Madam:
The Biotechnology Innovation Organization (BIO) thanks to the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments regarding the Draft Guidance, Qualification Process for Drug Development Tools.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place.
BIO commends the Agency for the development of the Draft Guidance on Qualification Process for Drug Development Tools (DDTs) as required by the 21st Century Cures Act. BIO believes that the Draft Guidance provides a useful framework for how new DDTs can be developed and used as well as the process for qualification of such tools, information that will be essential to Sponsors looking to qualify a DDT. BIO has included in this letter several recommendations for FDA’s consideration as the Guidance is finalized including flexibility in timelines, identification of meetings types, detail regarding rescinding or modification of DDTs, alignment of CDRH regulation, use of external experts, and information on prioritization of review.
Download Full Comments Below
BIO letter on Qualification Process for Drug Development Tools
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
Re: Docket No. FDA–2020-D-0529: FDA Draft Guidance, Qualification Process for Drug Development Tools
Dear Sir/Madam:
The Biotechnology Innovation Organization (BIO) thanks to the Food and Drug Administration (FDA or Agency) for the opportunity to submit comments regarding the Draft Guidance, Qualification Process for Drug Development Tools.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place.
BIO commends the Agency for the development of the Draft Guidance on Qualification Process for Drug Development Tools (DDTs) as required by the 21st Century Cures Act. BIO believes that the Draft Guidance provides a useful framework for how new DDTs can be developed and used as well as the process for qualification of such tools, information that will be essential to Sponsors looking to qualify a DDT. BIO has included in this letter several recommendations for FDA’s consideration as the Guidance is finalized including flexibility in timelines, identification of meetings types, detail regarding rescinding or modification of DDTs, alignment of CDRH regulation, use of external experts, and information on prioritization of review.